Hotel Leela

Warming up for new guests

Revenues in line, but bottomline succumbs to cost pressures

Hotel Leela reported a topline of INR4.3bn, drop of 4% YoY, in line with our estimates. The company faced pressures on employee, F&B and other operating costs thus bringing the EBIDTA margins down by 545bp to 29% at INR 1.26bn in FY10. Hotel Leela has reported net profit of INR410mn in FY10 as against INR812mn in FY09, down 50% due to benign occupancy and ARRs throughout the year.

Occupancy remains flat, ARR drops 20% in FY10

Hotel Leela recorded a flat occupancy at 64% while ARRs corrected by 20% YoY to INR9300 in FY10. The fourth quarter, however, showed clear signs of a revival with occupancy at 71% and ARR at INR10748 levels,- sequentially up from 69% and INR9800 respectively, as of Q3FY10. We believe Hotel Leela will benefit from the strong domestic revival due to its concentrated presence in key metro locations which invariably are the first to revive.

Delhi property to be operational in Aug'10; Chennai in Q1FY12

Hotel Leela would be commissioning its Delhi property in August 2010 with 260 rooms. The property would be a high-end, deluxe hotel and would open with rack rates of INR20000 plus. The Chennai project is expected to get delayed from the earlier timeline of Dec2010. The management has indicated that the Chennai hotel would commence in Q1FY12 with 332 rooms. We have made necessary changes in our assumptions of property launch timelines.

Growth momentum to continue with domestic revival

Domestic sector has shown clear signs of a revival from the third quarter onwards. We expect Hotel Leela to make a 23% topline growth in FY11 on the back of improved occupancy and ARRs along with the new launch in Delhi which is expected to ring in good business with the Commonwealth Games round the corner.

Maintain Accumulate; Balance sheet stresses to ease off

We have built in the expected delays in projects and thereby revised our FY11 and FY12 estimates. Hotel Leela is expected to present a healthy earnings growth going ahead with management focus on reducing balance sheet stresses. At CMP, Hotel Leela is fairly valued at INR 26.4mn FY12E EV/Room. We maintain our **Accumulate** and have revised our Target Price on Hotel Leela to INR50 valuing it at INR 27mn FY12E EV/Room, presenting 9% upside.



Rating : Accumulate

Target Price : INR50 Upside : 9%


CMP: INR46 (as on 2 June 2010)

Key data

1 US\$= INR47	
Face Value (INR)	2
Daily Vol. (3M NSE Avg.)	1,323,752
Mkt Cap (INRbn/US\$mn)	17.4 / 370.2
Current/Dil. Shares O/S (mn)	378/423
Bloomberg /Reuters Code	LELA IN/HTLE.BO

Source: Bloomberg ; * As on 2 June 2010

Price & volume



Source: Bloomberg

Institutional Investors 9.9 10.1 10.4 12.9 Other Investors 14.0 14.8 15.2 12.8 General Public 24.5 23.5 21.8 21.0 Source: Bloomberg					
Institutional Investors 9.9 10.1 10.4 12.9 Other Investors 14.0 14.8 15.2 12.6 General Public 24.5 23.5 21.8 21.0 Source: Bloomberg	Share holding (%)	Q1FY10	Q2FY10	Q3FY10	Q4FY10
Other Investors 14.0 14.8 15.2 12.8 General Public 24.5 23.5 21.8 21.0 Source: Bloomberg Price performance (%) 3M 6M 12M Sensex (0.2) (2.5) 12.6 Hotel leela (3.0) 10.8 10.4 Indian Hotels 6.4 13.8 26.7	Promoter	51.6	51.6	52.7	53.3
General Public 24.5 23.5 21.8 21.0 Source: Bloomberg 3M 6M 12M Price performance (%) 3M 6M 12M Sensex (0.2) (2.5) 12.0 Hotel leela (3.0) 10.8 10.4 Indian Hotels 6.4 13.8 26.7	Institutional Investors	9.9	10.1	10.4	12.9
Source: Bloomberg 3M 6M 12M Price performance (%) 3M 6M 12M Sensex (0.2) (2.5) 12.6 Hotel leela (3.0) 10.8 10.4 Indian Hotels 6.4 13.8 26.7	Other Investors	14.0	14.8	15.2	12.8
Price performance (%) 3M 6M 12M Sensex (0.2) (2.5) 12.6 Hotel leela (3.0) 10.8 10.4 Indian Hotels 6.4 13.8 26.7	General Public	24.5	23.5	21.8	21.0
Sensex (0.2) (2.5) 12.6 Hotel leela (3.0) 10.8 10.4 Indian Hotels 6.4 13.8 26.7	Source: Bloomberg				
Hotel leela (3.0) 10.8 10.4 Indian Hotels 6.4 13.8 26.7	Price performance	(%)	3M	6M	12M
Indian Hotels 6.4 13.8 26.7	Sensex		(0.2)	(2.5)	12.6
	Hotel leela		(3.0)	10.8	10.4
EIH (5.6) (16.5) (13.9	Indian Hotels		6.4	13.8	26.7
	EIH		(5.6)	(16.5)	(13.9)

Source: Bloomberg


Key Financials											
Y/E Mar (INR mn)	Rev	YoY (%)	EBITDA	EBITDA (%)	Adj PAT	YoY (%) F	ully DEPS	RoE (%)	RoCE (%)	EV/EBITDA (x)	EV/Adj. Room
FY08	5,146	23.8	2,300	44.7	1,501	18.6	3.5	14.0	6.0	16.0	33.1
FY09	4,522	(12.1)	1,559	34.5	1,459	(2.8)	3.4	7.4	2.1	26.7	39.2
FY10	4,362	(3.6)	1,266	29.0	404	(72.3)	1.0	2.0	1.2	36.6	37.5
FY11E	5,385	23.5	1,925	35.7	652	61.4	1.5	2.9	2.0	25.4	25.3
FY12E	6,480	20.3	2,490	38.4	949	45.7	2.2	4.1	2.9	20.0	26.4

Source: Company, Elara Securities Estimate

Financials


Financials				
Income Statement (INR mn)	FY09	FY10	FY11E	FY12E
Net Revenues	4,522	4,362	5,385	6,480
EBITDA	1,559	1,266	1,925	2,490
Less :- Depreciation & Amortization	633	683	907	943
EBIT	926	583	1,019	1,547
Add:- Other Income	1,299	262	653	653
Less:- Interest Expenses	267	245	766	882
PBT	1,958	600	905	1,319
Less :- Taxes	476	196	253	369
Adjusted PAT	1,482	404	652	949
Reported PAT	1,459	404	652	949
Balance Sheet (INR mn)	FY09	FY10E	FY11E	FY12E
Share Capital	756	756	847	847
Reserves	18,645	19,292	21,891	22,593
Borrowings	24,495	29,364	29,434	29,889
Deferred Tax (Net)	1,004	1,004	1,004	1,004
Total Liabilities	44,899	50,415	53,175	54,333
Gross Block	38,335	39,305	54,945	55,445
Less:- Accumulated Depreciation	3,985	4,633	5,540	6,482
Net Block	34,350	34,671	49,405	48,962
Add:- Capital work in progress	9,345	13,775	1,935	3,935
Investments	462	462	462	462
Net Working Capital	741	1,506	1,373	972
Other Assets	0.15	0.15	0.05	0.05
Total Assets	44,899	50,415	53,175	54,333
Cash Flow Statement (INR mn)	FY09	FY10E	FY11E	FY12E
Cash profit adjusted for non cash items	2,005	1,330	1,467	1,645
Add/Less : Working Capital Changes	1,165	(600)	(298)	(5)
Operating Cash Flow	3,170	730	1,169	1,640
Less:- Capex	17,591	5,435	3,800	2,500
Free Cash Flow	(14,421)	(4,705)	(2,631)	(860)
Financing Cash Flow	3,882	4,869	2,200	455
Investing Cash Flow	(18,053)	(5,435)	(3,800)	(2,500)
Net change in Cash	(11,000)	164	(431)	(405)
Ratio Analysis	FY09	FY10E	FY11E	FY12E
Income Statement Ratios(%)				
Revenue Growth	(12.1)	(3.6)	23.5	20.3
EBITDA Growth	(32.2)	(18.8)	52.1	29.3
PAT Growth	(2.8)	(72.3)	61.4	45.7
EBITDA Margin	34.5	29.0	35.7	38.4
Net Margin	32.3	9.3	12.1	14.7
Return & Liquidity Ratios (%)				
Net Debt/Equity (x)	1.2	1.4	1.3	1.3
ROE (%)	7.4	2.0	2.9	4.1
ROCE (%)	2.1	1.2	2.0	2.9
Per Share data & Valuation Ratios				
Diluted EPS (INR/Share)	3.4	1.0	1.5	2.2
EPS Growth (%)	(2.8)	(71.9)	58.9	45.7
DPS (INR/Share)	0.5	0.2	0.2	0.6
P/E Ratio (x)	11.9	42.4	29.9	20.5
EV/EBITDA (x)	26.7	36.6	25.4	20.0
EV/Adj. Room (INR mn)	39.2	37.5	25.3	26.4
EV/Sales (x)	0.9	1.1	0.9	0.8
Price/Book (x)	0.9	0.9	0.9	0.8
Dividend Yield (%)	1.0	0.3	0.5	1.3
Source: Company, Elara Socurities Estimate				

Revenue & margins growth trend




Source: Company, Elara Securities Estimate

Adjusted profits growth trend



Source: Company, Elara Securities Estimate

Return ratios



Source: Company, Elara Securities Estimate


Source: Company, Elara Securities Estimate

Q4 brings signs of buoyancy

Occupancy stays flat; ARR drops 20% in FY10

Hotel Leela recorded a flat occupancy at 64% while ARRs corrected by 20% YoY to INR9300 in FY10. The fourth quarter showed clear signs of a revival with occupancy at 71% and ARR at INR10748 levels, both sequentially up from 69% and INR9800 respectively in Q3FY10. We believe Hotel Leela will benefit from the strong domestic revival due to its concentrated presence in key metro locations - usually the first to revive.

Exhibit 1: Occupancy improves in H2FY10 (%)



Source: Company, Elara Securities Research




Exhibit 2: ARRs show significant growth in Q4 (INR)

Delhi property to be operational in Aug'10; Chennai in Q1FY12


Q3FY10

Q4FY10

■Q1FY10 ■Q2FY10

Hotel Leela would be commissioning its Delhi property in August 2010 with 260 rooms. The property would be a high-end, deluxe hotel and would open with rack rates of INR 20000 plus. The Chennai project is expected to get delayed from the earlier timeline of Dec2010. The management has indicated that the Chennai hotel would commence in Q1FY12 with 332 rooms. We have made necessary changes in our assumptions of property launch timelines.





Source: Elara Securities Research

FY11 topline to show strong growth of 23%

Domestic revival to sustain growth momentum

Domestic sector has shown clear signs of a revival from the third quarter onwards. We expect Hotel Leela to make a 23% topline growth in FY11 on the back of improved occupancy and ARRs along with the new launch in Delhi which is expected to bring in good business with the Commonwealth Games round the corner.

Focus on reducing balance sheet stresses

The management has indicated that it is focused on reducing the debt and easing off the banace sheet pressures in FY11. Hotel Leela's outstanding 39.2mn Euro FCCBs would be up for redemption in Sep2010, which would see an outflow of around INR2.8bn. The company is looking to raise INR7.5bn via QIP or the FCCB route. We also expect the divestment of IT park in Chennai at around INR1.8bn to ease out debt pressures.


Maintain Accumulate with 9% upside

We have built in the expected delays in projects and thereby, revised our FY11 and FY12 estimates. Hotel Leela is likely to present a healthy earnings growth going ahead egged on by improving sector drivers. At the CMP, Hotel Leela is fairly valued at INR 26.4mn FY12E EV/Room. The stock currently trades at an expensive 20x FY12E EV/EBIDTA but on a 17% discount to its FY12E book value of INR55. We maintain our Accumulate and have revised our Target Price on Hotel Leela to INR50, valuing it at INR 27mn FY12E EV/Room, presenting 9% upside.

Source: Company, Elara Securities Research

ElaraCapital

Coverage History



	Date	Rating	Target Price	Closing Price
1	17-Mar-2010	Accumulate	INR54	INR47
2	2-Jun-2010	Accumulate	INR50	INR46

Guide to Research Rating

BUY	Absolute Return >+20%
ACCUMULATE	Absolute Return +5% to +20%
REDUCE	Absolute Return -5% to +5%
SELL	Absolute Return < -5%

Disclosures & Confidentiality

The Note is based on our estimates and is being provided to you (herein referred to as the "Recipient") only for information purposes. The sole purpose of this Note is to provide preliminary information on the business activities of the company and the projected financial statements in order to assist the recipient in understanding / evaluating the Proposal. Nothing in this document should be construed as an advice to buy or sell or solicitation to buy or sell the securities of companies referred to in this document. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved) and should consult its own advisors to determine the merits and risks of such an investment. Nevertheless, Elara or any of its affiliates is committed to provide independent and transparent recommendation to its client and would be happy to provide any information in response to specific client queries. Elara or any of its affiliates have not independently verified all the information given in this Note and expressly disclaim all liability for any errors and/or omissions, representations or warranties, expressed or implied as contained in this Note. The user assumes the entire risk of any use made of this information. Elara or any of its affiliates, their directors and the employees may from time to time, effect or have effected an own account transaction in or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for or solicit investment banking or other business from any company referred to in this Note. Each of these entities functions as a separate, distinct and independent of each other. This Note is strictly confidential and is being furnished to you solely for your information. This Note should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This Note is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Elara or any of its affiliates to any registration or licensing requirements within such jurisdiction. The distribution of this document in certain jurisdictions may be restricted by law, and persons in whose possession this document comes, should inform themselves about and observe, any such restrictions. Upon request, the Recipient will promptly return all material received from the company and/or the Advisors without retaining any copies thereof. The Information given in this document is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This Information is subject to change without any prior notice. Elara or any of its affiliates reserves the right to make modifications and alterations to this statement as may be required from time to time. However, Elara is under no obligation to update or keep the information current. Neither Elara nor any of its affiliates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. This Note should not be deemed an indication of the state of affairs of the company nor shall it constitute an indication that there has been no change in the business or state of affairs of the company since the date of publication of this Note. The disclosures of interest statements incorporated in this document are provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. Elara Securities (India) Private Limited generally prohibits its analysts, persons reporting to analysts and their family members from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Any clarifications / queries on the proposal as well as any future communication regarding the proposal should be addressed to Elara Securities (India) Private Limited / the company.

Disclaimer

The information contained in this note is of a general nature and is not intended to address the circumstances of any particular individual or entity. Although we endeavor to provide accurate and timely information, there can be no guarantee that such information is accurate as of the date it is received or that it will continue to be accurate in the future. No one should act on such information without appropriate professional advice after a thorough examination of the particular situation.



India

Kalpataru Synergy, 6th Level, East Wing, Opp Grand Hyatt, Santacruz East, Mumbai – 400 055, India Tel : +91 22 4062 6868 Europe 29 Marylebone Road, London NW1 5JX, United Kingdom Tel : +44 20 7486 9733 **USA** 535 Fifth Avenue 29th Floor New York, NY 10017 Tel : 646-884-7130 **Asia / Pacific** 20, RAFFLES PLACE, # 14-02 OCEAN TOWERS, Singapore 048620 Tel : +65 6536 6267

Head - Institu	utional Equities & Global Research	harendra.kumar@elaracapital.com	+91 22 4062 6871		
			-		
Global Head Sales & Trading					
London	+44 78 5057 7329	joseph.mammen@elaracapital.com	+44 20 7467 5578		
London	+44 75 9527 9712	david.somekh@elaracapital.com	+44 20 7299 2577		
London	+44 79 1208 7272	jonathan.camissar@elaracapital.com	+44 20 7299 2575		
India	+91 98334 77685	prashin.lalvani@elaracapital.com	+91 22 4062 6844		
India	+91 98676 96668	koushik.vasudevan@elaracapital.com	+91 22 4062 6841		
India	+91 98676 96661	amit.mamgain@elaracapital.com	+91 22 4062 6843		
9					
India	+91 98334 99217	ananthanarayan.iyer@elaracapital.cor	n +91 22 4062 6856		
India	+91 98694 07973	vishal.thakker@elaracapital.com	+91 22 4062 6857		
	Global Head S London London London India India India India	London +44 78 5057 7329 London +44 75 9527 9712 London +44 79 1208 7272 India +91 98334 77685 India +91 98676 96668 India +91 98676 96661 India +91 98334 99217	Global Head Sales & Trading London +44 78 5057 7329 joseph.mammen@elaracapital.com London +44 75 9527 9712 david.somekh@elaracapital.com London +44 79 1208 7272 jonathan.camissar@elaracapital.com India +91 98334 77685 prashin.lalvani@elaracapital.com India +91 98676 96668 koushik.vasudevan@elaracapital.com India +91 98676 96661 amit.mamgain@elaracapital.com India +91 98334 99217 ananthanarayan.iyer@elaracapital.com		

Research				
Abhinav Bhandari	Analyst	Construction, Infrastructure	abhinav.bhandari@elaracapital.com	+91 22 4062 6807
Aliasgar Shakir	Analyst	Mid caps	aliasgar.shakir@elaracapital.com	+91 22 4062 6816
Alok Deshpande	Analyst	Oil & Gas	alok.deshpande@elaracapital.com	+91 22 4062 6804
Amol Bhutada	Analyst	Auto & Auto Ancillaries	amol.bhutada@elaracapital.com	+91 22 4062 6806
Himani Singh	Analyst	FMCG, Hotels, Hospitals	himani.singh@elaracapital.com	+91 22 4062 6801
Mohan Lal	Analyst	Media & Retail	mohan.lal@elaracapital.com	+91 22 4062 6802
Pralay Das	Analyst	Information Technology	pralay.das@elaracapital.com	+91 22 4062 6808
Ravindra Deshpande	Analyst	Metals & Cement	ravindra.deshpande@elaracapital.com	+91 22 4062 6805
Ravi Sodah	Analyst	Cement	ravi.sodah@elaracapital.com	+91 22 4062 6817
Satyender Khatter	Analyst	Banking & Telecom	satyender.khatter@elaracapital.com	+91 22 4062 6809
Sumant Kumar	Analyst	FMCG	sumant.kumar@elaracapital.com	+91 22 4062 6803
Surajit Pal	Analyst	Pharmaceuticals	surajit.pal@elaracapital.com	+91 22 4062 6810
Kavitha Rajan	Associate	Telecom	kavitha.rajan@elaracapital.com	+91 22 4062 6814
Pooja Sharma	Associate		pooja.sharma@elaracapital.com	+91 22 4062 6819
Saira Ansari	Associate		saira.ansari@elaracapital.com	+91 22 4062 6812
Tarun Kapila	Associate		tarun.kapila@elaracapital.com	+91 22 4062 6811
Sreevalsan Menon	Editor		sreevalsan.menon@elaracapital.com	+91 22 4062 6813
Gurunath Parab	Production		gurunath.parab@elaracapital.com	+91 22 4062 6815

Access our reports on Bloomberg: Type ESEC <GO>

Also available on Thomson & Reuters

Member (NSE, BSE)

Regn Nos: CAPITAL MARKET SEBI REGN. NO.: BSE: INB 011289833, NSE: INB 231289837 DERIVATIVES SEBI REGN. NO.: NSE: INF 231289837 CLEARING CODE: M51449.

Website: www.elaracapital.com Investor Grievance Email ID: investor.grievances@elaracapital.com